Key result
In 15 adult male rats with cerebral ischemia, IC87201 reversed ischemia-induced worsening of heart rate variability parameters at 48 hours, including recovery of SDRR.
Why the study?
Heart rate variability evaluates autonomic disorders after cerebral ischemia, and the study investigated the therapeutic potential of IC87201 in reducing post-stroke cardiac dysfunction.
Does IC87201 improve heart rate variability in a rat model of middle cerebral artery occlusion?
Does IC87201 improve heart rate variability in a rat model of middle cerebral artery occlusion?
In a rat model of cerebral ischemia, IC87201 effectively reversed ischemia-induced worsening of heart rate variability parameters, suggesting potential for treating post-ischemic cardiac dysfunction.
Answers are grounded in this paper and cite their sources.
May support IC87201 for post-stroke autonomic recovery in rats; hypothesis-generating and leaves open human translation.
Objective: Assessment of heart rate variability (HRV) is a non-invasive and reliable method to evaluate autonomic disorders after cerebral ischemia. The present study was conducted to investigate the therapeutic potential of IC87201 in reducing post-stroke cardiac dysfunction. Materials and methods: Cerebral ischemia was induced by the middle cerebral artery occlusion (MCAO) method in 15 anesthetized adult male rats in three MCAO, MCAO+ DXM, and MCAO+ IC87201 groups, for one hour. Electrocardiogram was recorded before, and 48 hours after ischemia and drug administration, and HRV parameters were calculated from R-R intervals. In the treatment groups, IC87201 and Dextromethorphan hydrobromide monohydrate (DXM) were injected after an ischemic period. Results: After brain ischemia, the R-R interval decreased and consequently heart rate increased. The R-R intervals were used to extract the HRV frequency and time domains, including normalized low frequency (LF), high frequency (HF), LF/HF ratio, and standard deviation of R-R interval (SDRR). Normalized LF and LF/HF ratio enhanced 48 hours after ischemia, while normalized HF and SDRR significantly reduced compared to the pre-ischemic state. All HRV parameters had returned to their pre-ischemic level 48 hours after IC87201 and DXM administration, except SDRR, which recovered only in the IC87201 administered group. Conclusion: Based on our findings, it can be concluded that cerebral ischemia significantly worsens HRV parameters as a result of sympathetic overactivity. These changes were reversed by administering DXM and IC87201, but IC87201 has generally been more effective in lowering lesions. As a result, IC87201 can be introduced as an effective substance for the treatment of post-ischemic cardiac side effects.
No takes yet. Share an insight, caveat, or question.
Mohammadian et al. (2023) studied Cerebral ischemia (n=15). IC87201 vs. MCAO alone and MCAO + DXM was evaluated on Heart rate variability (HRV) parameters (normalized LF, HF, LF/HF ratio, SDRR). In 15 adult male rats with cerebral ischemia, IC87201 reversed ischemia-induced worsening of heart rate variability parameters at 48 hours, including recovery of SDRR.
Synapse has enriched 10 related papers. Consider them for comparative context: